Endo begins shipping first Zetia generic

DUBLIN — Endo announced Thursday that its Par Pharmaceutical had begun shipping the first generic version of Zetia (ezetimibe) tablets. The drug is indicated to reduce elevated LDL cholesterol in patients with hyperlipidemia. 

 

Par’s generic is entitled to market exclusivity based on the first-to-file status of the application filed by its licensing partners, Glenmark Pharmaceuticals USA. 

 

The drug will be available in 10-mg dosage strength. U.S. sales of Zetia were bout $2.61 billion for the 12 months ended September 30.